209 related articles for article (PubMed ID: 34513704)
1. Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Li S; Wang T; Tong G; Li X; You D; Cong M
Front Oncol; 2021; 11():726257. PubMed ID: 34513704
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy.
Kuang T; Zhang L; Qiu Z; Zhang Y; Wang W
Front Immunol; 2023; 14():1261202. PubMed ID: 38077332
[TBL] [Abstract][Full Text] [Related]
3. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers.
Lilong Z; Kuang T; Li M; Li X; Hu P; Deng W; Wang W
Clin Nutr; 2024 Jan; 43(1):31-41. PubMed ID: 38000193
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
Sacdalan DB; Lucero JA; Sacdalan DL
Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
[TBL] [Abstract][Full Text] [Related]
5. Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.
Ji H; Liu B; Jin P; Li Y; Cui L; Jin S; Wu J; Shan Y; Zhang Z; Ming J; Zhang L; Du C
Front Immunol; 2024; 15():1364728. PubMed ID: 38665913
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
Zou Y; Zou X; Zheng S; Tang H; Zhang L; Liu P; Xie X
Ther Adv Med Oncol; 2020; 12():1758835920940928. PubMed ID: 32874208
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis.
Febriyanto T; Muhammad F; Wijaya W; Oey O; Simadibrata DM
Urol Oncol; 2024 May; 42(5):160.e11-160.e23. PubMed ID: 38101990
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis.
Chen H; Wang D; Zhong Q; Tao Y; Zhou Y; Shi Y
Cancer Immunol Immunother; 2020 Dec; 69(12):2413-2424. PubMed ID: 32749571
[TBL] [Abstract][Full Text] [Related]
10. When the Loss Costs Too Much: A Systematic Review and Meta-Analysis of Sarcopenia in Head and Neck Cancer.
Hua X; Liu S; Liao JF; Wen W; Long ZQ; Lu ZJ; Guo L; Lin HX
Front Oncol; 2019; 9():1561. PubMed ID: 32117787
[No Abstract] [Full Text] [Related]
11. Prognostic significance of CT-determined sarcopenia in older patients with advanced squamous cell lung cancer treated with programmed death-1 inhibitors.
Ying L; Xu L; Yang J; Zhang Q
Sci Rep; 2024 May; 14(1):12025. PubMed ID: 38797769
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
Ababneh O; Ghazou A; Alawajneh M; Alhaj Mohammad S; Bani-Hani A; Alrabadi N; Shreenivas A
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473262
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis.
You Y; Jiang C; Peng K; He W; Wang L; Jin Y; Xia L
Cancer Immunol Immunother; 2021 Aug; 70(8):2323-2335. PubMed ID: 33512554
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Oct; 70(10):2771-2780. PubMed ID: 33625531
[TBL] [Abstract][Full Text] [Related]
15. Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review.
Zhang R; Wang F; You Z; Deng D; He J; Yan W; Quan J; Wang J; Yan S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):82. PubMed ID: 38319412
[TBL] [Abstract][Full Text] [Related]
16. The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies.
Wilson BE; Routy B; Nagrial A; Chin VT
Cancer Immunol Immunother; 2020 Mar; 69(3):343-354. PubMed ID: 31865400
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
Liu X; Li S; Ke L; Cui H
BMC Cancer; 2024 Apr; 24(1):490. PubMed ID: 38632528
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma.
Liu T; Wang G; Chen C; He L; Wang R
Jpn J Radiol; 2024 May; ():. PubMed ID: 38727962
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy.
Yang H; Cong T; Luo Y; Yang C; Ren J; Li X
J Hepatocell Carcinoma; 2024; 11():175-189. PubMed ID: 38283695
[TBL] [Abstract][Full Text] [Related]
20. Impact of Computed Tomography-Based, Artificial Intelligence-Driven Volumetric Sarcopenia on Survival Outcomes in Early Cervical Cancer.
Han Q; Kim SI; Yoon SH; Kim TM; Kang HC; Kim HJ; Cho JY; Kim JW
Front Oncol; 2021; 11():741071. PubMed ID: 34631578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
